Equine Laminitis Drug Undergoing Testing

Laminil, a drug being tested for use in horses, is reported to have been successful in stopping the signs of laminitis in 80% of horses treated so far. Utilizing an ingredient that is approved for human use, Laminil is an injectible drug treatment that works by inhibiting the inflammation that causes pain and destroys tissue structures within the hoof. Good results have been seen in treated horses suffering from both acute and chronic laminitis.

Testing in the U.S. and Dubai has led to relief in many horses that have developed laminitis for various reasons including equine metabolic syndrome, overconsumption of grain or grass, trauma, and unrelieved weight-bearing. So far, no adverse effects have been noted.

Second only to colic, laminitis is a leading cause of death in horses. One estimate puts the risk of developing laminitis at about 3 to 4% of all horses in each year. Once the inflammatory reaction begins, it is difficult to treat because tissue damage occurs as circulation is disrupted. By the time the horse shows signs of discomfort, it is often too late to bring about a full recovery, though some horses return to a sound state after a bout of this disease.

Affected horses are needed for further drug trials. Veterinarians treating laminitic horses can access the “For Veterinarians” page at www.laminil.us to see if the horses may qualify for the trial.